Products from TransMed7's technology pipeline currently under development are designed to address critical healthcare needs in medical fields such as breast health; soft tissue surgery, including small or fragile tissues and challenging surgical spaces, with endoscopy, laparoscopy, and robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.
"This new strategic partnership with Peridot enables TransMed7 to launch new products such as our Concorde and Martinet technologies directly into the market immediately following FDA clearance. Peridot was our contract manufacturer for our SpeedBird platform needle sets, and we are excited to be expanding our relationship with Peridot for timed product commercial release in significant quantities for strategic market penetration," said Eugene H. Vetter, TransMed7's Co-Founder and CEO.
TransMed7 is focused on the development of minimally invasive medical devices. With particular expertise in both oncologic and cardiovascular disease, the company and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices.
Peridot offers complete end-to-end precision manufacturing and clean room assembly services to a wide range of industries. With over twenty years' experience with device fabrication and precision miniature and micro-miniature component assembly, the company can design, prototype, test and deliver products with precision and versatility.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid